Clinical Trial

Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This trial studies how well iohexol works in helping doctors calculate the dose of carboplatin given to patients with cancer. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Understanding how to best calculate the dose of carboplatin given to patients with cancer may help doctors learn how to improve the use of carboplatin in the future.
Protocol Amendment History 3 changes
notable Enrollment increased: 318 -> 350 participants 2026-08-08
notable Primary completion pushed: 2027-02-06 -> 2028-03-14 2026-08-08
minor Completion pushed: 2028-02-06 -> 2028-03-14 2026-08-08
Trial Details
NCT Number NCT03997370
Lead Sponsor NRG Oncology
Collaborators: National Cancer Institute (NCI)
Conditions Malignant Solid Neoplasm
Enrollment 350 participants
Start Date 2020-01-15
Primary Completion 2028-03-14 (estimated)
Study Completion 2028-03-14 (estimated)
Updated on ClinicalTrials.gov 2026-08-07